Abstract
SAR exploration at P1' using an anti-succinate-based macrocyclic hydroxamic acid as a template led to the identification of several bulky biphenylmethyl P1' derivatives which confer potent porcine TACE and anti-TNF-alpha cellular activities with high selectivity versus most of the MMPs screened. Our studies demonstrate for the first time that TACE has a larger S1' pocket in comparison to MMPs and that potent and selective TACE inhibitors can be achieved by incorporation of sterically bulky P1' residues.
MeSH terms
-
ADAM Proteins
-
ADAM17 Protein
-
Binding Sites
-
Heterocyclic Compounds, 1-Ring / chemical synthesis*
-
Heterocyclic Compounds, 1-Ring / chemistry
-
Heterocyclic Compounds, 1-Ring / pharmacology
-
Humans
-
Hydroxamic Acids / chemical synthesis*
-
Hydroxamic Acids / chemistry
-
Hydroxamic Acids / pharmacology
-
Lipopolysaccharides / pharmacology
-
Metalloendopeptidases / antagonists & inhibitors*
-
Models, Molecular
-
Protease Inhibitors / chemical synthesis*
-
Protease Inhibitors / chemistry
-
Protease Inhibitors / pharmacology
-
Protein Binding
-
Structure-Activity Relationship
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
2,11-diaza--4-(2-(trifluoromethyl)phenyl)-5-(hydroxyaminocarbonyl)-1-((((piperazin-1-yl)carbonyl)methyl)aminocarbonyl)-9-oxa-3,10-dioxocyclopentadecane
-
2,11-diaza-4-(2-(trifluoromethyl)phenyl)-5-(hydroxyaminocarbonyl)-1-((((morpholin-4-yl)carbonyl)methyl)aminocarbonyl)-9-oxa-3,10-dioxocyclopentadecane
-
Heterocyclic Compounds, 1-Ring
-
Hydroxamic Acids
-
Lipopolysaccharides
-
Protease Inhibitors
-
Tumor Necrosis Factor-alpha
-
ADAM Proteins
-
Metalloendopeptidases
-
ADAM17 Protein
-
ADAM17 protein, human